ADC Therapeutics (ADCT)

• Market cap: $303M
• 1 day: 63.02%
• 5 days: 27.24%
• 1 month: -2.19%
• 3 months: 15.93%
• 6 months: -10.06%
• Year to date: 85.21%
• 1 year: 192.52%
• 5 years: -89.44%
• 10 years: -89.44%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.

Employees: 274

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

191% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 11

141% more call options, than puts

Call options by funds: $265K | Put options by funds: $110K

19% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 16

4% more funds holding

Funds holding: 75 [Q2] → 78 (+3) [Q3]

0% less capital invested

Capital invested by funds: $173M [Q2] → $173M (-$181K) [Q3]

0.17% less ownership

Funds ownership: 56.94% [Q2] → 56.76% (-0.17%) [Q3]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q2] → 2 (-1) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $6 92% upside
• Avg. target: $6 92% upside
• High target: $6 92% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Stephens & Co. Sudan Loganathan 44% 1-year accuracy 7 / 16 met price target

92% upside $6

Overweight Initiated

8 Nov 2024